Incorrect password
evipedia.ai Suggest Edit

St. John's Wort for Health & Longevity

Evidence Review created on 05/09/2026 using AI4L / Opus 4.7

Also known as: Hypericum perforatum, Hypericum, SJW, Tipton’s Weed, Klamath Weed, Goatweed

Motivation

St. John’s Wort (Hypericum perforatum) is a yellow-flowering perennial herb whose standardized extracts have become one of the most extensively studied botanical interventions for mood and mild-to-moderate depressive states. The herb acts on multiple neurotransmitter systems while strongly inducing the body’s main drug-metabolizing enzymes, a property that shapes both its therapeutic appeal and its safety profile.

Once a folk remedy associated with the feast of St. John the Baptist, the plant moved into mainstream phytotherapy in Europe during the late twentieth century, where standardized extracts became common options for milder mood disorders. A growing body of clinical trial data — including comparisons against modern antidepressants — has positioned it as a candidate for evidence-based use, while drug interactions have generated equally serious cautions. For health- and longevity-oriented adults, mood resilience and stable cognition are foundational pillars, and the herb’s broad enzyme-induction effects can ripple through any optimization stack built on prescription or supplement co-therapies.

This review examines the evidence supporting and challenging the use of St. John’s Wort, its proposed mechanisms, the practical realities of dosing and standardization, and the interactions and safety considerations that shape how it is used.

Benefits - Risks - Protocol - Conclusion

This section presents high-level overviews of St. John’s Wort from trusted longevity-oriented experts and publications, focusing on substantive coverage of its pharmacology, evidence base, and practical use.

  • St. John’s Wort: An Herbal Antidepressant? - Life Extension Magazine

    A long-form magazine article reviewing the standardized extract evidence base for depression, with discussion of hyperforin’s mechanism and how the herb compares to prescription antidepressants in clinical trials.

  • Treating Depression without Drugs - Part II - Chris Kresser

    A functional-medicine perspective on St. John’s Wort as one of three drug-free options for depression, covering the placebo-controlled evidence base, dosing considerations, and the mood-related mechanism in an integrative-care context.

  • Clinical Relevance of St. John’s Wort Drug Interactions Revisited - Nicolussi et al., 2020

    A narrative review covering the pharmacokinetic and pharmacodynamic interactions of St. John’s Wort, with detailed discussion of CYP (cytochrome P450, a family of liver enzymes that metabolize most prescription drugs) and transporter induction and the clinical scenarios where these interactions matter most.

  • St. John’s Wort and Depression: In Depth - National Center for Complementary and Integrative Health

    A comprehensive overview from the U.S. NIH-affiliated body covering history, evidence for depression severity tiers, drug interactions, and safety concerns; the depth and structured format make it a strong orientation document. The NCCIH (National Center for Complementary and Integrative Health, a U.S. government research center) is a federally funded body whose guideline framing typically aligns with mainstream pharmaceutical regulation and may therefore weight botanical evidence more conservatively than industry-funded reviews.

  • Hypericum perforatum in the Treatment of Psychiatric and Neurodegenerative Disorders: Current Evidence and Potential Mechanisms of Action - Zirak et al., 2019

    A narrative review covering the in vitro, in vivo, and clinical evidence for Hypericum perforatum with attention to hyperforin and hypericin pharmacology, antidepressant mechanisms, and broader neuropsychiatric applications.

A direct search of Rhonda Patrick’s foundmyfitness.com, Peter Attia’s peterattiamd.com, and Andrew Huberman’s hubermanlab.com did not surface a substantive, dedicated piece on St. John’s Wort. The list above prioritizes the available depth-of-coverage sources from the remaining priority experts (Chris Kresser and Life Extension Magazine) and supplements them with high-quality botanical-medicine references. Note that Life Extension Magazine articles can reflect a commercial interest in supplement sales — this should be considered when weighing claims.

Grokipedia

Hypericum perforatum

A general-knowledge encyclopedia entry covering the botany, chemistry, traditional uses, regulatory status, and clinical evidence base of Hypericum perforatum, useful as a quick orientation to the herb.

Examine

St. John’s Wort

A structured supplement page summarizing the human-evidence base for St. John’s Wort across mood and other outcomes, with grading of each effect by study quality and a comprehensive interactions section.

ConsumerLab

St. John’s Wort Supplements Review

An independent product-testing review evaluating commercially available St. John’s Wort products for label accuracy of hypericin and hyperforin, contamination, and disintegration, plus a brand-by-brand quality summary.

Systematic Reviews

This section lists key systematic reviews and meta-analyses of St. John’s Wort, prioritizing those with the largest pooled samples, most recent publication, and direct relevance to its clinical applications.

Mechanism of Action

St. John’s Wort is a complex multi-constituent botanical with several pharmacologically active classes — most prominently the naphthodianthrones (hypericin, pseudohypericin), the phloroglucinols (hyperforin, adhyperforin), and a range of flavonoids. The current evidence places hyperforin as the principal driver of mood-related activity, with hypericin and flavonoids contributing supporting effects.

  • Monoamine modulation: Hyperforin inhibits the reuptake of serotonin, norepinephrine, dopamine, GABA (gamma-aminobutyric acid, the main inhibitory neurotransmitter), and glutamate, but does so through a non-classical mechanism — by activating the TRPC6 ion channel (a transient receptor potential channel involved in calcium signaling) and elevating intracellular sodium, rather than by directly blocking transporters.

  • Receptor binding: The extract has affinity for several central nervous system receptors implicated in mood, including sigma-1, GABA, and adenosine receptors, contributing to a broader neuropharmacological footprint than single-target SSRIs.

  • Anti-inflammatory and neuroprotective signaling: Hypericin and flavonoid constituents modulate NF-κB (a key inflammation-regulating transcription factor) and BDNF (brain-derived neurotrophic factor, a protein supporting neuron survival and plasticity), both implicated in depression pathophysiology.

  • Photosensitization: Hypericin is photoactive and, in high doses or sensitive individuals, generates reactive oxygen species in skin exposed to ultraviolet light — relevant to side-effect profile rather than therapeutic mechanism.

  • Competing mechanistic views: Earlier hypotheses framed St. John’s Wort primarily as a mild monoamine oxidase (MAO) inhibitor — an enzyme inhibitor blocking neurotransmitter breakdown. Subsequent work showed in vivo MAO inhibition is minimal at therapeutic doses, shifting the dominant model to hyperforin-driven reuptake modulation. Some researchers argue the herb’s effect cannot be fully explained by any single constituent and that synergy among constituents is essential.

  • Pharmacological properties: St. John’s Wort extracts are oral preparations with extensive enterohepatic recirculation. Hypericin has a long elimination half-life of roughly 24–48 hours; hyperforin’s half-life is approximately 9–12 hours. Tissue distribution is broad, including central nervous system penetration sufficient for receptor activity. Metabolism is hepatic, with the herb itself being a potent inducer of CYP3A4 and CYP2C9 (cytochrome P450 enzymes that metabolize a large fraction of prescription drugs), plus the P-glycoprotein efflux transporter (ABCB1, a gene encoding a pump that exports drugs from cells) — an action central to its drug-interaction profile.

Historical Context & Evolution

The original use of St. John’s Wort dates to classical antiquity, where Dioscorides and Galen documented its application for “melancholia,” wound healing, sciatica, and as a vermifuge. The plant’s traditional name derives from its peak flowering near the feast of St. John the Baptist on June 24, and medieval European practice attributed protective properties to it against malevolent spirits — which, in modern reading, parallels its later study for mood and anxiety states.

The transition into health optimization began in twentieth-century Europe, particularly Germany, where a research tradition around standardized phytomedicines led the German Commission E (a regulatory body whose monographs are influenced by member input from German phytomedicine manufacturers, who derived direct revenue from the conclusions endorsed for Hypericum products) to formally approve standardized extracts for mild-to-moderate depression in the 1980s. By the late 1990s, prescriptions of standardized Hypericum extracts in Germany rivaled or exceeded those of conventional antidepressants for mild depression — also a structural payer dynamic, since national health systems facing higher SSRI costs may have a systematic incentive to favor cheaper botanicals where evidence allows, a structural bias that can shape both guideline framing and research funding. This European clinical practice, paired with growing meta-analytic evidence, drove international interest, including in the United States.

Historical research findings — beyond folk uses — included controlled trials in the 1980s and 1990s comparing Hypericum extracts to placebo and to tricyclic antidepressants (an older class of antidepressants, e.g., amitriptyline and imipramine, that block reuptake of serotonin and norepinephrine). These early trials reported response rates similar to active comparators in mild-to-moderate depression with fewer adverse effects. Two prominent U.S. trials in the early 2000s (the Hypericum Depression Trial Study Group, 2002; Shelton et al., 2001) reported negative results in moderate-to-severe major depression, and these were widely characterized as having “debunked” the herb. The actual findings, however, are more nuanced: those trials enrolled patients with more severe depression than the European trials where positive results predominated, used different extracts and doses, and in some cases showed comparable failure of the active SSRI comparator — a feature consistent with placebo response in trial populations rather than with proof of inefficacy.

Subsequent meta-analyses, including Linde et al.’s Cochrane review and several updates through the 2020s, returned to a more measured position: St. John’s Wort extracts appear effective in mild-to-moderate depression at standardized doses, while evidence for severe depression remains weak — a more granular conclusion than the simpler “discredited” framing. The evolution of opinion thus reflects not new proof of inefficacy but shifting interpretation across populations, doses, and extract types, and the field continues to refine which patients and preparations show the most consistent benefit.

Expected Benefits

A dedicated search across clinical literature, regulatory monographs, and expert sources was performed before writing this section to ensure the benefit profile is comprehensive.

High 🟩 🟩 🟩

Mild-to-Moderate Depression

Standardized St. John’s Wort extracts have shown efficacy comparable to SSRIs and superiority over placebo in mild-to-moderate depression, supported by multiple Cochrane and independent meta-analyses pooling thousands of patients. The proposed mechanism is multi-target monoamine reuptake modulation driven primarily by hyperforin. The signal is strongest with extracts standardized to hyperforin content (e.g., WS 5570, LI 160, ZE 117) and at doses typically in the 600–1,800 mg/day range; trials in severe major depression have not consistently shown efficacy.

Magnitude: Response rates in pooled trials approximately 28% higher than placebo and statistically equivalent to SSRIs (relative risk — the ratio of event probability between groups — near 1.0 versus standard antidepressants) on Hamilton Depression Rating Scale (a clinician-rated questionnaire scoring depression severity) outcomes.

Medium 🟩 🟩

Somatoform Disorders and Anxiety with Depressive Features

In trials including patients with mixed anxiety-depression and somatoform symptoms (physical symptoms without clear organic cause), standardized Hypericum extracts have outperformed placebo on composite anxiety-depression scales. The proposed mechanism overlaps with mood effects via monoamine modulation and possible GABAergic activity. The evidence base is smaller than for depression alone, and trial populations are heterogeneous.

Magnitude: Modest effect sizes (Cohen’s d ≈ 0.3–0.5; d is a standardized effect-size measure where 0.2 is small, 0.5 medium, 0.8 large) versus placebo across small randomized trials.

Menopausal Vasomotor and Mood Symptoms

Several randomized trials and a focused meta-analysis report that St. John’s Wort, alone or combined with black cohosh, reduces hot flash frequency and improves mood scores in perimenopausal and postmenopausal women. The mechanism likely combines central monoamine modulation with possible mild estrogenic activity from flavonoid constituents.

Magnitude: Reductions of approximately 50% in daily hot flash frequency reported in some trials, with mood-score improvements of 30–40% on validated menopause symptom scales.

Low 🟩

Seasonal Affective Disorder

Small randomized and open-label trials suggest standardized extracts may improve symptoms of winter-pattern seasonal affective disorder, with some evidence of additive effect when combined with bright light therapy. The mechanism likely overlaps with depression efficacy. Trial size and heterogeneity limit the strength of inference.

Magnitude: Symptom score reductions of 30–50% on Hamilton scales reported in small open trials, comparable to or slightly less than light therapy alone.

Premenstrual Syndrome and PMDD

Limited randomized evidence supports modest improvements in mood-related premenstrual symptoms (PMS) and possibly in physical premenstrual complaints. The proposed mechanism is serotonergic modulation, paralleling SSRI use in premenstrual dysphoric disorder (PMDD — a severe premenstrual mood condition).

Magnitude: Reductions of approximately 50% in mood-component PMS scores in two small RCTs; no consistent effect on physical symptoms.

Topical Wound Healing and Mild Skin Inflammation

Topical formulations of Hypericum oil have shown modest acceleration of wound healing and reduction of mild inflammatory skin conditions in small clinical studies. The proposed mechanism is hyperforin’s antibacterial activity combined with anti-inflammatory effects of flavonoids and tannins.

Magnitude: Wound closure rates 20–30% faster than control vehicle in small trials of post-surgical and minor wounds.

Speculative 🟨

Smoking Cessation Support

Mechanistic interest in St. John’s Wort for nicotine withdrawal stems from its monoamine activity and parallels with bupropion. Two randomized trials, however, found no advantage over placebo, and the totality of evidence remains too thin to support efficacy. The basis for continued interest is mechanistic and anecdotal rather than clinical.

Neuroprotective and Longevity-Relevant Effects

Preclinical models suggest hypericin and flavonoid constituents reduce oxidative stress, modulate BDNF, and protect neurons from glutamate excitotoxicity. No controlled human trials have evaluated cognitive aging or neurodegenerative outcomes. The basis is mechanistic only.

Antiviral and Anticancer Activity

Hypericin shows photosensitizing activity exploited in experimental photodynamic therapy for certain cancers and antiviral effects in vitro. Outside of investigational photodynamic protocols, no clinical evidence supports oral St. John’s Wort for cancer or viral disease, and the basis is mechanistic and isolated case reports.

Benefit-Modifying Factors

  • CYP and transporter polymorphisms: Variants in CYP3A4, CYP2C9, and ABCB1 (the gene encoding P-glycoprotein, an efflux pump) can alter both the herb’s exposure and the magnitude of its enzyme-induction effect, indirectly modifying both efficacy and interaction risk.

  • Baseline serotonin and depression severity markers: Patients with milder baseline severity (Hamilton scores roughly 17–24) appear to benefit most consistently; baseline biomarkers suggesting inflammation-driven depression (elevated high-sensitivity C-reactive protein, hs-CRP) may also predict response, though this is not fully established.

  • Sex-based differences: Women, particularly perimenopausal and postmenopausal women, show consistently strong response rates in trials, possibly reflecting interaction with estrogen-modulated mood pathways. Men also respond, but most large trials have been female-predominant.

  • Pre-existing health conditions: Co-existing anxiety disorders may amplify perceived benefit; co-existing bipolar spectrum disorders can shift the risk-benefit balance unfavorably (see Risks). Photosensitive skin conditions reduce the tolerability ceiling.

  • Age-related considerations: Older adults, often on multiple medications, benefit similarly to younger adults on efficacy metrics but face disproportionately higher interaction risk that can reduce the net benefit. Hepatic clearance changes with age may also influence steady-state exposure.

Potential Risks & Side Effects

A dedicated search across drug references including drugs.com, the FDA (Food and Drug Administration, the U.S. agency that regulates drugs and supplements) NCCIH monograph, and prescribing-information-style summaries was performed before writing this section to ensure the risk profile is comprehensive.

High 🟥 🟥 🟥

Cytochrome P450 and P-glycoprotein Induction Causing Drug Failure

St. John’s Wort is one of the most potent botanical inducers of CYP3A4, CYP2C9, and the ABCB1 efflux transporter. Through this induction it can substantially lower plasma concentrations of many co-administered medications — including immunosuppressants (cyclosporine, tacrolimus), oral contraceptives, certain antiretrovirals, anticoagulants such as warfarin, several oncology agents, and others. Documented consequences include transplant rejection, contraceptive failure with unintended pregnancy, and treatment failure of antiretroviral and oncology regimens. Effects develop over 1–2 weeks of dosing and can persist for weeks after discontinuation.

Magnitude: Reductions of approximately 30–70% in plasma concentrations of CYP3A4 substrates such as cyclosporine, indinavir, midazolam, and several others reported across pharmacokinetic studies.

Serotonin Syndrome When Combined with Serotonergic Drugs

Combining St. John’s Wort with SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tramadol, triptans, MAO inhibitors, or other serotonergic agents can precipitate serotonin syndrome — a potentially severe condition with agitation, hyperthermia, neuromuscular hyperactivity, and autonomic instability. Reports include both mild presentations and severe cases requiring hospitalization. Older adults and those on multiple serotonergic agents are at highest risk.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Photosensitivity

Hypericin is photoactive, and ingestion of standardized extracts can increase skin sensitivity to ultraviolet light. Mild photosensitivity (sunburn at lower-than-usual exposure) is reported in clinical trials at typical doses; severe phototoxic reactions occur primarily at very high doses or in fair-skinned individuals with intense sun exposure. The mechanism is generation of reactive oxygen species by photoexcited hypericin in the skin.

Magnitude: Reported in roughly 1–3% of trial participants at standard doses; higher in fair-skinned individuals and at doses above 1,800 mg/day.

Switch to Mania or Hypomania in Bipolar Spectrum Disorders

Like conventional antidepressants, St. John’s Wort can precipitate manic or hypomanic switches in patients with undiagnosed or inadequately treated bipolar disorder. Cases include both clear manic episodes and softer hypomanic shifts. The mechanism parallels that of monoamine-modulating antidepressants.

Magnitude: Not quantified in available studies.

Gastrointestinal Side Effects

Mild gastrointestinal effects — nausea, dyspepsia, diarrhea, abdominal discomfort — are the most common adverse events at therapeutic doses. They are usually transient and rarely cause discontinuation. The mechanism is unclear but may involve direct mucosal effects of polyphenols and tannins.

Magnitude: Reported in 5–15% of users at standard doses across clinical trials, generally similar to or lower than rates with SSRIs.

Low 🟥

Sexual Dysfunction

Decreased libido and delayed orgasm are reported but appear less frequent and less severe than with SSRIs. The mechanism is presumed to overlap with serotonergic modulation. Reports are inconsistent across trials, and many patients tolerate St. John’s Wort better sexually than prescription antidepressants.

Magnitude: Reported in 1–5% of users at standard doses; substantially lower than the 25–73% rates reported with SSRIs.

Headache, Restlessness, and Insomnia

A subset of users report headache, restlessness, or sleep disturbance, particularly during the first 1–2 weeks of dosing or with evening administration. The mechanism is presumed monoaminergic activation. These typically attenuate with continued use or with morning-only dosing.

Magnitude: Reported in 2–8% of trial participants; severity is usually mild.

Withdrawal-Like Symptoms on Abrupt Discontinuation

Abrupt discontinuation after extended use has been associated with malaise, headache, and rebound mood symptoms in some users, paralleling the discontinuation syndromes seen with conventional antidepressants. Mechanism likely involves adaptive changes in monoamine receptor sensitivity.

Magnitude: Not quantified in available studies.

Speculative 🟨

Mechanistic concern that long-term photoactive hypericin in the lens could accelerate ultraviolet-induced lens damage has been raised, but no controlled epidemiologic data confirm this risk. The basis is mechanistic and isolated case reports.

Cognitive or Cardiovascular Effects from CYP-Mediated Loss of Other Drug Effects

By reducing exposure to statins, certain antihypertensives, or antiarrhythmics, St. John’s Wort could theoretically worsen cardiovascular and cognitive trajectories in patients depending on those drugs. The basis is mechanistic plus pharmacokinetic evidence; no controlled outcome trials have isolated this effect.

Risk-Modifying Factors

  • CYP2C9 and ABCB1 polymorphisms: Reduced-function variants can amplify St. John’s Wort’s effect on co-administered substrates, increasing both the magnitude of induction and the variability of the resulting drug exposure.

  • Baseline biomarker considerations: Patients on warfarin should have baseline international normalized ratio (INR — a clotting time measure) before initiation; transplant patients should have baseline immunosuppressant trough levels documented if any Hypericum exposure is being considered.

  • Sex-based differences: Women on combined oral contraceptives are at distinctively high risk because reduced contraceptive plasma levels can result in unintended pregnancy; this risk has no equivalent in men.

  • Pre-existing health conditions: Bipolar spectrum disorders, organ transplant status, HIV (human immunodeficiency virus, the virus that causes AIDS, when on antiretrovirals), and active oncology treatment are conditions where the risk profile shifts dramatically. Photosensitive skin conditions including porphyria (a group of rare blood disorders that cause severe skin photosensitivity) are also relevant.

  • Age-related considerations: Older adults are usually on more co-medications and therefore disproportionately exposed to interaction risks; reduced renal and hepatic reserve can also amplify effects of any drug whose levels rise unexpectedly when Hypericum is later discontinued.

Key Interactions & Contraindications

  • Immunosuppressants: Cyclosporine and tacrolimus levels can fall by 30–60%, with documented cases of acute transplant rejection. Severity: absolute contraindication in transplant recipients. Clinical consequence: graft loss.

  • Oral contraceptives: Ethinyl estradiol and norethindrone exposures can decrease by 15–30%, with breakthrough bleeding and reported unintended pregnancies. Severity: caution; combined hormonal contraception users should use additional non-hormonal contraception or choose a different intervention. Mitigating action: switch to non-CYP-dependent contraception methods (copper IUD, an intrauterine device that prevents pregnancy without hormones) or avoid St. John’s Wort.

  • Anticoagulants: Warfarin INR can decrease by 20–40%. Severity: caution; requires monitoring. Mitigating action: weekly INR for 4 weeks after starting and after discontinuation, with dose adjustment by the prescriber.

  • Antiretrovirals: Indinavir levels can fall by approximately 50%; similar effects on other protease inhibitors and non-nucleoside reverse transcriptase inhibitors. Severity: absolute contraindication in patients on antiretroviral therapy. Clinical consequence: viral rebound and resistance.

  • Oncology agents: Imatinib, irinotecan, and several tyrosine kinase inhibitors (e.g., erlotinib) show substantial reductions. Severity: absolute contraindication during active oncology treatment.

  • Cardiovascular drugs: Digoxin AUC (area under the concentration–time curve, a measure of total drug exposure) can fall by approximately 25%; some statins (simvastatin, atorvastatin), several calcium-channel blockers, and certain antiarrhythmics are similarly affected. Severity: caution; monitor.

  • CNS-active medications: Concurrent use with SSRIs (fluoxetine, sertraline), SNRIs (venlafaxine, duloxetine), MAO inhibitors (phenelzine, tranylcypromine), tramadol, triptans, or buspirone risks serotonin syndrome. Severity: absolute contraindication for the combination; St. John’s Wort should not be added to ongoing serotonergic therapy.

  • Anesthetics: Some interactions with anesthetic agents have been reported; patients should disclose use before any surgery and discontinue 1–2 weeks beforehand. Severity: caution; mitigation: pre-surgical washout.

  • Over-the-counter medications: Dextromethorphan (a cough suppressant) raises serotonin syndrome concerns when combined; loperamide and certain antihistamines can have altered exposure via P-glycoprotein induction. Severity: caution.

  • Supplement interactions: Combinations with other serotonergic supplements — 5-HTP (5-hydroxytryptophan, a serotonin precursor), L-tryptophan, S-adenosyl methionine (SAMe), or high-dose Rhodiola — increase serotonin syndrome risk and should be avoided. Severity: caution to absolute avoidance.

  • Additive interactions: Sedative botanicals (valerian, kava) may potentiate central nervous system effects; caffeine and other stimulants may modify perceived activation effects; alcohol combinations are not well-studied but generally discouraged.

  • Populations who should avoid: Organ transplant recipients (any post-transplant time horizon, indefinitely), patients on antiretroviral therapy for HIV, patients on active oncology systemic therapy, patients with bipolar I or II disorder (relative contraindication), pregnant women (any trimester) or women breastfeeding (insufficient safety data), children under 18 years of age (off-label, evidence sparse), patients within 14 days of any planned surgery, patients with severe hepatic impairment (Child-Pugh Class B or C), patients with eGFR (estimated glomerular filtration rate, a measure of kidney function) < 30 mL/min/1.73 m², and patients on warfarin or other narrow-therapeutic-index drugs unless under close monitoring.

Risk Mitigation Strategies

  • Comprehensive medication and supplement reconciliation: Mitigates serotonin syndrome and CYP/P-glycoprotein interaction risk. Before initiation, every prescription drug, over-the-counter product, and supplement should be reviewed against an interaction database such as Lexicomp or Medscape; a clinician should be consulted whenever any narrow-therapeutic-index drug is on the list.

  • Choose standardized extracts only: Mitigates dose unpredictability and variable side-effect risk. Select products standardized to both hypericin (typically 0.3%) and hyperforin (typically 3–5%) and produced by a manufacturer with third-party testing; typical evidence-based daily doses are 600–1,800 mg/day in divided doses.

  • Slow-onset titration where appropriate: Mitigates initial gastrointestinal and activating side effects. Begin at 300 mg once daily for 3–7 days before increasing to a typical 300 mg three times daily, with the highest dose not later than mid-afternoon.

  • Photoprotection during treatment: Mitigates phototoxicity. Trial protocols and product labeling typically include consistent use of broad-spectrum SPF 30+ sunscreen, sun-protective clothing, and avoidance of tanning beds for the duration of dosing and 1–2 weeks after.

  • Pre-surgical and pre-procedure washout: Mitigates anesthetic interactions and bleeding-related uncertainties. Discontinue 10–14 days before any planned surgery, and disclose use to the anesthesiology team regardless.

  • INR monitoring on warfarin: Mitigates loss of anticoagulant effect. Weekly INR for 4 weeks after initiation and after discontinuation, with prescriber dose adjustment as needed.

  • Bipolar screening before initiation: Mitigates manic switch risk. Personal and family psychiatric history should be reviewed before any first-time use; patients with prior unexplained periods of decreased need for sleep, racing thoughts, or grandiosity should defer use pending psychiatric evaluation.

  • Backup contraception: Mitigates contraceptive failure. Women on combined hormonal contraception who cannot avoid Hypericum should add a non-hormonal method such as a copper intrauterine device or barrier methods for the duration of use and at least 4 weeks after.

  • Tapered discontinuation: Mitigates withdrawal-like symptoms. After more than 2–3 months of use, taper over 1–2 weeks rather than stopping abruptly.

Therapeutic Protocol

  • Standard standardized-extract protocol: As popularized by European phytomedicine practice and codified in German Commission E and several long-standing manufacturers (Steigerwald’s WS 5570 / Laif, Lichtwer’s LI 160 / Jarsin, Max Zeller’s ZE 117), the most commonly used dose is 300 mg of standardized extract three times daily (totaling 900 mg/day), with selected trials going up to 1,800 mg/day in moderate depression.

  • Integrative-medicine adjunctive protocol: Some integrative practitioners (e.g., as described in the writings of Chris Kresser and clinicians in the naturopathic literature) layer St. John’s Wort with foundational nutritional support — omega-3 EPA (eicosapentaenoic acid, an anti-inflammatory omega-3 fatty acid), vitamin D status optimization, and B-vitamin status checks — rather than as a sole intervention. This approach uses the same standardized doses but emphasizes baseline correction of nutrient deficiencies that overlap with depression risk.

  • Conventional-comparable approach: In countries where Hypericum extract is treated as a regulated medicine (Germany, parts of Europe), it is prescribed in the same workflow as a low-side-effect first-line antidepressant, with formal follow-up at 4–6 weeks and trial duration of at least 8–12 weeks before judging response. This is the framework used in most positive RCTs.

  • Best time of day: Morning and early-afternoon dosing is generally preferred; evening dosing can cause restlessness or interfere with sleep in a subset of users. A 300 mg morning + 300 mg midday + 300 mg early-afternoon split is more commonly tolerated than a late-evening dose.

  • Half-life considerations: Hyperforin’s half-life of approximately 9–12 hours and hypericin’s of 24–48 hours support divided dosing for stable plasma levels; once-daily extended-release formulations exist (e.g., WS 5570 once-daily 600 mg) and have been validated in RCTs.

  • Single versus split dose: Three-times-daily dosing is most evidence-supported, but once-daily 600 mg standardized formulations show comparable efficacy in randomized trials, primarily of WS 5570.

  • Genetic polymorphism considerations: CYP2C9 and CYP3A4 reduced-function variants and ABCB1 polymorphisms can shift exposure and the magnitude of induction effects; in highly polypharmacy patients, pharmacogenetic testing to anticipate co-medication effects is increasingly considered. APOE4 status (a genetic variant of apolipoprotein E associated with Alzheimer’s risk) is not directly relevant to Hypericum response.

  • Sex-based considerations: Women — particularly perimenopausal — have shown high response rates in trials; co-occurring vasomotor symptoms may benefit from the combination with black cohosh seen in menopause-focused trials. Contraceptive interactions are uniquely critical in women of reproductive age.

  • Age-related considerations: Older adults benefit similarly to younger adults but require especially careful medication reconciliation; starting at the lower end of the dose range (300–600 mg/day) is reasonable in those above 70 to assess tolerance.

  • Baseline biomarker considerations: Baseline INR (if on warfarin), thyroid function (since hypothyroidism mimics depression), vitamin D, B12, and ferritin checks are reasonable to rule out reversible contributors to mood symptoms before attributing response to the herb.

  • Pre-existing health conditions: Patients with mild depression and minimal co-medication are the strongest candidates; patients with severe depression, suicidality, bipolar features, or polypharmacy require more cautious or alternative approaches.

Discontinuation & Cycling

  • Lifelong versus short-term use: Most clinical evidence is for treatment courses of 6 weeks to 6 months; data extending to 1 year exist but are less robust. Use is typically time-limited rather than lifelong, with treatment continued until clinical response is sustained for 3–6 months and then tapered.

  • Withdrawal effects: Mild discontinuation symptoms — malaise, headache, transient mood dip — have been reported with abrupt cessation after extended use, paralleling SSRI discontinuation syndrome but generally milder.

  • Tapering protocol: After more than 2–3 months of dosing, a taper of 25% reduction every 5–7 days over 1–2 weeks is generally well tolerated; longer tapers may be appropriate for users at higher doses or with prior discontinuation difficulties.

  • Cycling for efficacy: Routine cycling is not established in the literature; sustained dosing throughout an acute treatment phase is the dominant pattern. Some practitioners structure seasonal-affective protocols around use during low-light months only, with annual cycling rather than continuous year-round dosing.

  • Restoration of CYP activity: CYP3A4 and CYP2C9 induction wanes over approximately 1–2 weeks after discontinuation; co-medications affected by the induction may require dose re-titration during this washout.

Sourcing and Quality

  • Standardization is the central quality consideration: The clinical evidence base is built on extracts standardized to a specified percentage of hypericin (typically 0.3%) and hyperforin (typically 3–5%). Products that disclose only “St. John’s Wort 300 mg” without standardization data fall outside the dosing assumptions of the supportive trial literature.

  • Third-party testing: Products carrying USP Verified, NSF, or ConsumerLab certifications provide stronger assurance of label accuracy and contamination control. Independent ConsumerLab reviews have documented past variation in real-world hypericin and hyperforin content versus label claims.

  • Reputable extract identifiers: Several standardized extracts have been used in successful clinical trials and serve as reliable benchmarks — WS 5570 (used in Steigerwald’s Laif), LI 160 (Lichtwer Pharma’s Jarsin), ZE 117 (Max Zeller’s Rebalance), and STW 3-VI. Note that each named extract was developed and is sold by the manufacturer that also funded much of the corresponding evidence; this is a direct financial conflict of interest in the supportive trial data and should be considered when interpreting the favorable signal. Products containing one of these named extracts at clinical-trial doses offer the highest confidence in dose-response translation.

  • Form considerations: Tablets and capsules of dried extract dominate the evidence base; tinctures vary widely in standardization and are less reliable for clinical dosing. Topical Hypericum oil is a separate preparation (used for skin and wound applications), not interchangeable with oral extracts.

  • Storage: Hyperforin in particular is unstable to heat, light, and oxygen; reputable products use stabilized formulations and protective packaging. Products stored in transparent bottles or past their expiration may have reduced active content.

Practical Considerations

  • Time to effect: Initial mood improvements typically begin at 2–4 weeks; full response usually requires 6–8 weeks. Early-week side effects (mild GI (gastrointestinal), activation) may precede therapeutic effect, mirroring conventional antidepressants.

  • Common pitfalls: Common errors include using non-standardized products with unpredictable potency, combining with an existing SSRI without medical guidance, failing to account for interactions with oral contraceptives or other prescription medications, sun exposure without photoprotection at higher doses, and abrupt discontinuation after extended use without tapering.

  • Regulatory status: In the United States, St. John’s Wort is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) and is not regulated by the FDA as a drug, with no approved medical claims. In Germany and several other European countries, standardized extracts are regulated as approved medicines for mild-to-moderate depression. Off-label use for premenstrual, menopausal, or seasonal mood symptoms is common but not formally approved.

  • Cost and accessibility: Standardized St. John’s Wort is widely accessible and inexpensive — typical month’s supply at trial doses costs roughly $10–$30 in the United States — making it one of the more affordable mood-targeted interventions. Higher-quality, third-party-verified branded extracts are at the upper end of that range.

Interaction with Foundational Habits

  • Sleep: The interaction is direct and mixed. Some users report improved sleep quality consistent with mood improvement; others — particularly those taking later-afternoon or evening doses — experience activation, restlessness, or insomnia. Mechanism is monoaminergic activation. Practical considerations: schedule the latest dose by mid-afternoon, avoid evening dosing in users with baseline sleep difficulty.

  • Nutrition: The interaction is indirect and predominantly minimal. Standard meals do not significantly alter absorption of standardized extracts, though high-fat meals may modestly reduce hyperforin absorption. Mechanism: hyperforin is lipophilic but absorbed adequately under usual feeding conditions. Practical considerations: consistent dosing relative to meals (e.g., always with food) reduces absorption variability; avoid combining with high-tyramine fermented foods if any MAO activity remains a concern, though this risk appears clinically minor.

  • Exercise: The interaction is mostly absent in direct terms but indirectly potentiating in mood outcomes. Aerobic exercise has independent antidepressant effects that may be additive with St. John’s Wort. Mechanism: complementary monoaminergic and BDNF effects. Practical considerations: combining structured exercise (3–5 sessions/week, including some moderate-vigorous activity) with herb dosing is consistent with how positive outcome trials typically allow concurrent activity.

  • Stress management: The interaction is indirect and potentiating. Mindfulness, breath-based practices, and cognitive-behavioral techniques target stress-system overactivation and combine well with monoaminergic modulation; mechanism overlap in HPA axis regulation (the body’s stress hormone system involving the hypothalamus, pituitary, and adrenal glands) and BDNF signaling. Practical considerations: pairing the intervention with a consistent stress-management practice generally produces better-sustained outcomes than the herb alone, mirroring patterns seen with conventional antidepressants in trials such as combined CBT (cognitive-behavioral therapy, a structured talk-therapy approach) + medication studies.

Monitoring Protocol & Defining Success

Trial protocols and clinical practice typically include a pre-treatment assessment before initiating St. John’s Wort to establish baseline mood and rule out reversible medical contributors to depressive symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
TSH 0.5–2.0 mIU/L Rule out hypothyroidism mimicking depression TSH (Thyroid-Stimulating Hormone) — conventional range 0.4–4.5 mIU/L; functional practitioners aim for the lower half. Fasting not required.
Free T3 3.2–4.4 pg/mL Assess active thyroid hormone status Best paired with TSH and free T4.
Vitamin D (25-OH) 40–60 ng/mL Low levels overlap with depressive symptoms Conventional range begins at 30 ng/mL; functional optimum higher. Fasting not required.
Vitamin B12 500–900 pg/mL Low B12 mimics depression and cognitive issues Conventional lower bound 200 pg/mL; functional minimum near 500. Pair with MMA (methylmalonic acid, a sensitive marker of B12 sufficiency) if borderline.
Folate (RBC) 400–800 ng/mL B-vitamin support for monoamine synthesis RBC (red blood cell) folate more reflective of stores than serum folate.
Ferritin 50–150 ng/mL (women); 100–300 ng/mL (men) Iron deficiency contributes to fatigue and low mood Conventional lower bound 15–30 ng/mL; functional optimum substantially higher. Pair with CBC (complete blood count, a standard panel of blood-cell measurements) and iron studies.
hs-CRP (high-sensitivity C-reactive protein) < 1.0 mg/L Inflammation-driven depression marker Avoid testing during acute infection; fasting not strictly required.
INR (if on warfarin) Patient-specific therapeutic range Detect anticoagulant attenuation from CYP induction Fasting not required; check weekly for 4 weeks after starting and after stopping Hypericum.
Liver enzymes (ALT, AST) < 30 U/L Baseline hepatic safety ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver-cell enzymes whose blood levels rise with hepatocyte injury. Useful before any extended hepatic-active intervention; fasting not required.

Ongoing monitoring should occur at 2 weeks (early tolerability check), 4–6 weeks (early response check), 8–12 weeks (full response assessment), and every 3–6 months thereafter for as long as the intervention is continued.

Beyond laboratory markers, qualitative tracking of subjective experience is central to evaluating St. John’s Wort:

  • Mood stability and frequency of low-mood days
  • Sleep onset and sleep quality
  • Energy levels and motivation
  • Cognitive clarity and concentration
  • Sexual function (changes in libido or orgasm)
  • Skin photosensitivity (sunburn at unusually low exposure)
  • Adherence to medication interactions and contraceptive backup if applicable

Emerging Research

  • Once-daily standardized extracts: Ongoing development and trials of once-daily formulations of WS 5570 and similar standardized extracts aim to improve adherence and standardize dosing further; published data already include positive non-inferiority results, with continued trials supporting label expansion in some jurisdictions.

  • Topical and procedural St. John’s Wort applications: Recent registered trials such as NCT07012278 (recruiting; ~80 women undergoing cesarean section; randomized controlled design; primary endpoint: REEDA-scale (Redness, Edema, Ecchymosis, Discharge, Approximation — a five-component clinician-rated wound-healing index) wound healing and Numeric Rating Scale pain at postpartum day 25) and NCT06839313 (recruiting; ~75 patients with recurrent aphthous stomatitis (recurring painful mouth ulcers, commonly called canker sores); randomized double-blind comparison versus triamcinolone and hyaluronic acid; primary endpoint: VAS (Visual Analog Scale, a patient-rated 0–10 line for symptom intensity) pain at days 0–7) investigate topical Hypericum perforatum preparations for wound healing and oral-ulcer pain.

  • Pharmacogenomic prediction of response: Future research evaluating CYP2D6 (cytochrome P450 2D6, a liver enzyme that metabolizes many psychiatric and cardiovascular drugs), CYP2C9, and ABCB1 variants as predictors of both response and interaction risk is active; published work (e.g., Nicolussi et al., 2020) reviews how genotype-driven variability in induction effects could foreshadow personalized risk-stratification approaches.

  • Relapse prevention in moderate depression: Industry-sponsored work such as NCT04315597 (completed; 398 outpatients with moderate major depression; Phase 3 placebo-controlled relapse-prevention design; primary endpoint: HAMD-17 (17-item Hamilton Depression Rating Scale) relapse rate over 24 weeks following a 12-week response phase on Laif 900 / STW 3-VI) examines whether standardized Hypericum extracts can sustain remission after acute response — a question central to the herb’s positioning relative to conventional maintenance antidepressants.

  • Photodynamic-therapy applications of hypericin: Outside the oral-extract context, NCT05073211 (completed; 31 participants with mild-to-moderate facial acne; randomized split-face design comparing St. John’s Wort photodynamic therapy versus indole-3-acetic acid photodynamic therapy; primary endpoint: change in number of acne lesions) and several other trials investigate hypericin as a photosensitizer in dermatologic photodynamic therapy. These represent a separate research stream that could weaken the case for routine oral use (if hypericin’s photoactive risk is reinforced) or strengthen it (if mechanistic understanding deepens).

  • Long-term safety in older adults: Future work evaluating cardiovascular and cognitive outcomes in older adults using St. John’s Wort as part of polypharmacy regimens is needed; currently published evidence is dominated by short-duration mood trials in younger adults, limiting confidence in long-term safety inferences.

  • Rigorous head-to-head comparisons in moderate-to-severe depression: Areas of future research that could change the current understanding include adequately powered head-to-head trials versus modern SNRIs and atypical antidepressants in moderate-to-severe depression, where current evidence remains weakest.

Conclusion

St. John’s Wort is a long-used flowering herb whose standardized extracts have generated one of the most extensive clinical evidence bases of any plant-derived intervention. The strongest signal is for mild-to-moderate low-mood symptoms, where standardized extracts have performed comparably to common prescription mood agents in pooled trial analyses, with generally fewer side effects. Secondary signals exist for menopausal mood and vasomotor symptoms, premenstrual mood symptoms, and seasonal mood patterns, while applications in severe depression, smoking cessation, and broader neuroprotection remain unsupported by current evidence.

The herb’s defining safety concern is not its direct side-effect profile — which is mild — but its potent activation of the body’s main drug-metabolizing enzymes and a transporter that pumps drugs out of cells. This activation can sharply lower the levels of many prescription medications, with documented cases of transplant rejection, contraceptive failure, and treatment loss for serious conditions including the human immunodeficiency virus and certain cancers. Combinations with other mood-active agents also carry a risk of a severe over-stimulation reaction.

Overall evidence quality is moderate-to-strong for mood uses and weak for most others, with the high-quality work concentrated in standardized European preparations. Conflicts of interest exist on multiple sides — extract manufacturers funding much of the positive evidence, and pharmaceutical interests favoring patentable alternatives — and both shape the literature. Translation of the favorable signal into real-world outcomes appears tied to product selection, interaction screening, and structured monitoring.

Top - Benefits - Risks - Protocol